APA (7th ed.) Citation

Mirolyubova, Y., Stadnik, E., Strugov, V., Andreeva, T., Nikulina, T., Virts, Y., . . . Zaritskey, A. Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia. Practical Medicine Publishing House.

Chicago Style (17th ed.) Citation

Mirolyubova, YuV, EA Stadnik, VV Strugov, TO Andreeva, TS Nikulina, YuV Virts, PA Butylin, AG Rumyantsev, and AYu Zaritskey. Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia. Practical Medicine Publishing House.

MLA (9th ed.) Citation

Mirolyubova, YuV, et al. Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia. Practical Medicine Publishing House.